LinkMed to change name to Allenex and relocate Swedish transplantation companies to one location

The LinkMed Board of Directors proposes to the Annual General Meeting to be convened on May 10 to change the name of the company from LinkMed AB to Allenex AB. All Swedish transplantation companies in the transplantation group will move to new common production and office facilities in Kungsholmen, Stockholm. Olerup SSP and AbSorber have already moved to the new premises and the parent company will follow in early May.

The strategic decision made in September 2010, to focus the future business on the transplantation field has led to a need to create a new common identity and a unified brand for the businesses in this area. The LinkMed Board of Directors therefore proposes to the Annual General Meeting May 10, 2011 to change its corporate name from LinkMed AB to Allenex AB for its future transplantation business.

  "The change of name to Allenex is an important step in further clarifying our new strategic focus on transplantation. The name Allenex has clear links to genetics (alleles) and transplantation (TX)," says Ingemar Lagerlof the CEO of LinkMed.

Olerup SSP and AbSorber are subsidiaries of LinkMed and part of the LinkMed Group. The Group also includes the U.S. sales company Olerup Inc. LinkMed AB will be the first company in the group to change name to Allenex.

For more information please contact:
Ingemar Lagerlöf, CEO LinkMed: +46 8 508 939 393
Okee Williams, Portfolio Manager LinkMed: +46 8 508 939 40

Or visit www.linkmed.se

LinkMed AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 14:45 (CET) on April 19, 2011.

LinkMed has two business areas, a commercial transplantation sector business with two subsidiaries and a venture portfolio comprising life science companies. The venture companies, all of which are associated companies, consist of four companies in drug development and biotechnology and six companies in diagnostics and medical technology. LinkMed is listed on NASDAQ OMX Stockholm, Small Cap sector (ticker symbol: LMED).

About Us

LinkMed, in collaboration with innovators, develops new life science companies. By contributing entrepreneurship and capital, LinkMed has created a portfolio of eleven companies, six in biotechnology and five in medical technology. The LinkMed share is listed on the OMX Nordic Exchange Stockholm in the small-cap sector (ticker:LMED). The company’s largest owners are FastPartner, Koncentra Holding, and the founder Ingemar Lagerlöf. See www.linkmed.se for more information.

Documents & Links